Online inquiry

IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12264MR)

This product GTTS-WQ12264MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Systemic sclerosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12264MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12943MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ11007MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ3297MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ1028MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ9296MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ15481MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ6986MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ2999MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW